Registration

COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) for COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC)

Firm
Client
Income
—
Expenses
—

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Budget/Appropriations BUD

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Pharmacy PHA

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Medical/Disease Research/Clinical Labs MED

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Science/Technology SCI

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Trade (domestic/foreign) TRD

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Taxation/Internal Revenue Code TAX

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Health Issues HCR

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Government Issues GOV

FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing

LobbyistCovered position, as disclosed
GREGORY ARONIN New —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.